Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.44%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.20, delivering a surprise of 600%.Over the last four quarter ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39450 HARMONY BIOSCIENCES ...

Exhibit 99.1 HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study N ...

The market expects Harmony Biosciences Holdings, Inc. (HRMY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which ...

Harmony Biosciences Holdings, Inc. (HRMY) shares rallied 6.7% in the last trading session to close at $39.79. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.2% gain over the past four weeks. Last month, the company announced robust financial results for the second quarter of 2024. Harmony's approved product, Wakix (pitolisant) is driving revenues while the company is making good progress with the studies o ...

Harmony Biosciences Holdings, Inc. (HRMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a prove ...

Core Viewpoint - Harmony Biosciences (HRMY) is identified as a strong value stock, currently undervalued compared to its industry peers, with favorable valuation metrics and a positive earnings outlook [3][7]. Valuation Metrics - HRMY has a Price-to-Book (P/B) ratio of 3.80, which is lower than the industry average of 4.72, indicating potential undervaluation [4]. - The Price-to-Sales (P/S) ratio for HRMY stands at 3.15, significantly below the industry average of 6.69, suggesting that the stock may be undervalued based on revenue [5]. - HRMY's Price-to-Cash Flow (P/CF) ratio is 14.95, compared to the industry average of 20.61, further supporting the notion of undervaluation [6]. Historical Performance - Over the past 52 weeks, HRMY's P/B ratio has fluctuated between a high of 4.83 and a low of 2.34, with a median of 3.66, indicating variability in market perception [4]. - The P/CF ratio for HRMY has ranged from a low of 6.65 to a high of 15.28, with a median of 11.14, reflecting its cash flow performance over the past year [6].

Company Overview - Harmony Biosciences Holdings, Inc. specializes in developing treatments for rare neurological diseases that are often overlooked by others [2] - The company was established in 2017 by Paragon Biosciences, LLC and is headquartered in Plymouth Meeting, PA [2] - Harmony's team is composed of experts from various disciplines, driven by the belief that innovative science leads to therapeutic possibilities for patients [2] Upcoming Events - Harmony's management team will participate in the Wells Fargo 2024 Healthcare Conference in Boston on September 5, 2024, at 9:30 a.m. ET [1] - The company will also take part in the 2024 Cantor Global Healthcare Conference in New York City on September 17, 2024, at 3:05 p.m. ET [1] - A webcast of the fireside chats from these conferences will be available on Harmony's investor page [1]

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...